Top Markets
Coin of the day
Pharvaris N.V. Pharvaris N.V.

Pharvaris N.V.

PHVS
Rank in Stocks #5577
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Share Price
$36.98
Last synced: 2026-08-26
Market Cap
$2.58B
Change (1 day)
-0.67%
Change (1 year)
55.51%
Country
NL
Trade Pharvaris N.V. (PHVS)

Category

Number of shares outstanding for Pharvaris N.V. (PHVS)
Number of shares outstanding as of August 2026: 0
According to Pharvaris N.V. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Pharvaris N.V. (PHVS) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
253.90M -
US
62.19M -
NL
396.00M -
US
478.91M -
AU
- -
CH